{"id":340495,"date":"2026-11-05T13:23:32","date_gmt":"2026-11-05T07:53:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340495"},"modified":"2026-11-05T13:23:32","modified_gmt":"2026-11-05T07:53:32","slug":"solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/","title":{"rendered":"3 Solar Photovoltaic Modules Maker, Banking Software Products Company and Branded Generics Maker Stocks With a Strong Future Roadmap: Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals: ROE of 14.7% to 26.2% and FY22 to FY26 revenue CAGR of 12.1% to 65.1%. Prices as of 4 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three solar module, banking software and drug stocks to watch are Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals. Their return on equity ranges from 14.7% to 26.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 65.1%. Saatvik Green Energy leads on both return on equity at 26.2% and revenue growth at 65.1% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Solar module, banking software and drug stocks give investors a way to track businesses that sit close to everyday demand in India. Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals cover a solar photovoltaic modules maker, a banking software products company and a branded generics maker.<\/p>\n<p>This list covers three solar module, banking software and drug stocks with complete current figures: Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#What_Are_Solar_Module_Banking_Software_and_Drug_Stocks\" title=\"What Are Solar Module, Banking Software and Drug Stocks?\">What Are Solar Module, Banking Software and Drug Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Solar_Module_Banking_Software_and_Drug_Stocks_at_a_Glance\" title=\"Solar Module, Banking Software and Drug Stocks at a Glance\">Solar Module, Banking Software and Drug Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Why_Do_Solar_Module_Banking_Software_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Solar Module, Banking Software and Drug Stocks Have a Strong Roadmap in India?\">Why Do Solar Module, Banking Software and Drug Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Why_Saatvik_Green_Energy_Features_Among_These_Solar_Module_Banking_Software_and_Drug_Stocks\" title=\"Why Saatvik Green Energy Features Among These Solar Module, Banking Software and Drug Stocks\">Why Saatvik Green Energy Features Among These Solar Module, Banking Software and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Why_Nucleus_Software_Exports_Features_Among_These_Solar_Module_Banking_Software_and_Drug_Stocks\" title=\"Why Nucleus Software Exports Features Among These Solar Module, Banking Software and Drug Stocks\">Why Nucleus Software Exports Features Among These Solar Module, Banking Software and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Why_Emcure_Pharmaceuticals_Features_Among_These_Solar_Module_Banking_Software_and_Drug_Stocks\" title=\"Why Emcure Pharmaceuticals Features Among These Solar Module, Banking Software and Drug Stocks\">Why Emcure Pharmaceuticals Features Among These Solar Module, Banking Software and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Saatvik_Green_Energy_vs_Nucleus_Software_Exports_vs_Emcure_Pharmaceuticals_on_Key_Financials\" title=\"Saatvik Green Energy vs Nucleus Software Exports vs Emcure Pharmaceuticals on Key Financials\">Saatvik Green Energy vs Nucleus Software Exports vs Emcure Pharmaceuticals on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Key_Risks_to_Check_Before_Investing_in_Solar_Module_Banking_Software_and_Drug_Stocks\" title=\"Key Risks to Check Before Investing in Solar Module, Banking Software and Drug Stocks\">Key Risks to Check Before Investing in Solar Module, Banking Software and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Final_Thoughts_on_Solar_Module_Banking_Software_and_Drug_Stocks\" title=\"Final Thoughts on Solar Module, Banking Software and Drug Stocks\">Final Thoughts on Solar Module, Banking Software and Drug Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#What_are_solar_module_banking_software_and_drug_stocks\" title=\"What are solar module, banking software and drug stocks?\">What are solar module, banking software and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Which_solar_module_banking_software_and_drug_stocks_are_covered_in_this_list\" title=\"Which solar module, banking software and drug stocks are covered in this list?\">Which solar module, banking software and drug stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Why_do_solar_module_banking_software_and_drug_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do solar module, banking software and drug stocks have a strong future roadmap in India?\">Why do solar module, banking software and drug stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#How_has_Saatvik_Green_Energy_performed_financially\" title=\"How has Saatvik Green Energy performed financially?\">How has Saatvik Green Energy performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#How_has_Nucleus_Software_Exports_performed_financially\" title=\"How has Nucleus Software Exports performed financially?\">How has Nucleus Software Exports performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#How_has_Emcure_Pharmaceuticals_performed_financially\" title=\"How has Emcure Pharmaceuticals performed financially?\">How has Emcure Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#What_risks_should_investors_check_before_buying_solar_module_banking_software_and_drug_stocks\" title=\"What risks should investors check before buying solar module, banking software and drug stocks?\">What risks should investors check before buying solar module, banking software and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/solar-photovoltaic-modules-maker-banking-software-products-company-and-branded-generics-maker-stocks-roadmap-lookout-list\/#Is_this_list_of_solar_module_banking_software_and_drug_stocks_investment_advice\" title=\"Is this list of solar module, banking software and drug stocks investment advice?\">Is this list of solar module, banking software and drug stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Solar_Module_Banking_Software_and_Drug_Stocks\"><\/span><strong>What Are Solar Module, Banking Software and Drug Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Solar module, banking software and drug stocks are listed companies that make solar photovoltaic modules, build software products for banks and lenders, and sell branded generics in India and other markets. Their earnings depend on solar installations, bank technology budgets and prescriptions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Solar_Module_Banking_Software_and_Drug_Stocks_at_a_Glance\"><\/span><strong>Solar Module, Banking Software and Drug Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/saatvikgl\/saatvik-green-energy-ltd-share-price-today\">Saatvik Green Energy<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">368.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,934<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">43.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.69<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/nucleus\/nucleus-software-exports-ltd-share-price-today\">Nucleus Software Exports<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">628.85<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,731<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">Emcure Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,160.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,487<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.31<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing solar module, banking software and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Solar_Module_Banking_Software_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Solar Module, Banking Software and Drug Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Solar module, banking software and drug stocks have a strong roadmap in India because large solar capacity plans, rising bank technology spending and steady demand for branded generics keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Solar modules.<\/strong> Capacity additions need panels.<\/li>\n<li><strong>Banking software.<\/strong> Lenders keep upgrading platforms.<\/li>\n<li><strong>Branded generics.<\/strong> Doctors prescribe trusted brands.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Saatvik_Green_Energy_Features_Among_These_Solar_Module_Banking_Software_and_Drug_Stocks\"><\/span><strong>Why Saatvik Green Energy Features Among These Solar Module, Banking Software and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the solar module, banking software and drug stocks on this list, Saatvik Green Energy is a Haryana-based manufacturer of solar photovoltaic modules and cells that supplies utility-scale, commercial and rooftop solar projects.<\/p>\n<p>Revenue rose from Rs 618 crore in FY22 to Rs 4,588 crore in FY26, a compound annual growth rate of 65.1%. Net profit grew from Rs 217 crore in FY25 to Rs 357 crore in FY26, a rise of 64.5%.<\/p>\n<p>The company has a return on equity of 26.2%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 4,934 crore. The stock trades at a P\/E of 20.1, below the industry P\/E of 43.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding module and cell capacity to meet rising demand for locally made solar equipment and is building a more integrated production chain. India&#8217;s solar capacity targets support a steady flow of orders.<\/p>\n<p><strong>What to watch:<\/strong> Track capacity additions, order book growth and solar policy support.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Nucleus_Software_Exports_Features_Among_These_Solar_Module_Banking_Software_and_Drug_Stocks\"><\/span><strong>Why Nucleus Software Exports Features Among These Solar Module, Banking Software and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the clean energy, fintech and pharma shares on this list, Nucleus Software Exports is a Noida-based software products company that builds lending and transaction banking software, with its FinnAxia and FinnOne platforms used by banks and financial institutions in India and overseas.<\/p>\n<p>The company has a return on equity of 14.7%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,731 crore. The stock trades at a P\/E of 16.4, below the industry P\/E of 17.5.<\/p>\n<p>Revenue rose from Rs 532 crore in FY22 to Rs 940 crore in FY26, a compound annual growth rate of 15.3%. Net profit grew from Rs 40.9 crore in FY22 to Rs 117 crore in FY26, which works out to a compound annual growth rate of 30.0%.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving customers to cloud-based and subscription offerings, which build recurring revenue over time. Banks upgrading lending and transaction systems create steady demand for its platforms.<\/p>\n<p><strong>What to watch:<\/strong> Monitor licence and subscription revenue and the pace of new customer wins.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Emcure_Pharmaceuticals_Features_Among_These_Solar_Module_Banking_Software_and_Drug_Stocks\"><\/span><strong>Why Emcure Pharmaceuticals Features Among These Solar Module, Banking Software and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.<\/p>\n<p>Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.<\/p>\n<p>In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> It is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<p><strong>What to watch:<\/strong> Look at the growth of the India branded business and the pace of new launches abroad.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Saatvik_Green_Energy_vs_Nucleus_Software_Exports_vs_Emcure_Pharmaceuticals_on_Key_Financials\"><\/span><strong>Saatvik Green Energy vs Nucleus Software Exports vs Emcure Pharmaceuticals on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three solar module, banking software and drug stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Saatvik Green Energy<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">618<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,588<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">65.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">357<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Nucleus Software Exports<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">532<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">940<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">117<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Emcure Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,919<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,335<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">941<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Saatvik Green Energy posts the highest return on equity in this group at 26.2%. Emcure Pharmaceuticals has the largest FY26 revenue at Rs 9,335 crore, and Saatvik Green Energy shows the fastest revenue growth with a 65.1% compound annual rate. A useful habit with solar module, banking software and drug stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Solar_Module_Banking_Software_and_Drug_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Solar Module, Banking Software and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these solar module, banking software and drug stocks, the main points are: Long-term clean energy, fintech and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Module prices.<\/strong> Solar equipment prices and policy support can change returns.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter solar module, banking software and drug stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Solar_Module_Banking_Software_and_Drug_Stocks\"><\/span><strong>Final Thoughts on Solar Module, Banking Software and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Solar module, banking software and drug stocks work best when investors track growth, valuation and return on equity side by side. Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals each have a clear plan to grow. Based on the 4 November 2026 close, Saatvik Green Energy trades at Rs 368.5, Nucleus Software Exports at Rs 628.85 and Emcure Pharmaceuticals at Rs 2,160.4.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track solar module, banking software and drug stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_solar_module_banking_software_and_drug_stocks\"><\/span><strong>What are solar module, banking software and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Solar module, banking software and drug stocks are listed companies that make solar photovoltaic modules, build software products for banks and lenders, and sell branded generics in India and other markets. Their earnings depend on solar installations, bank technology budgets and prescriptions. This list looks at three of them, Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_solar_module_banking_software_and_drug_stocks_are_covered_in_this_list\"><\/span><strong>Which solar module, banking software and drug stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals. Based on the 4 November 2026 close, Saatvik Green Energy traded at Rs 368.5, Nucleus Software Exports at Rs 628.85 and Emcure Pharmaceuticals at Rs 2,160.4. Their return on equity ranges from 14.7% to 26.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 65.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_solar_module_banking_software_and_drug_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do solar module, banking software and drug stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Solar module, banking software and drug stocks have a strong roadmap in India because large solar capacity plans, rising bank technology spending and steady demand for branded generics keep widening the market for these companies. The main drivers are as follows. Solar modules. Capacity additions need panels. Banking software. Lenders keep upgrading platforms. Branded generics. Doctors prescribe trusted brands. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Saatvik_Green_Energy_performed_financially\"><\/span><strong>How has Saatvik Green Energy performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 618 crore in FY22 to Rs 4,588 crore in FY26, a compound annual growth rate of 65.1%. Net profit grew from Rs 217 crore in FY25 to Rs 357 crore in FY26, a rise of 64.5%. The company has a return on equity of 26.2%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 4,934 crore. The stock trades at a P\/E of 20.1, below the industry P\/E of 43.9. Looking ahead, the company is adding module and cell capacity to meet rising demand for locally made solar equipment and is building a more integrated production chain. India&#8217;s solar capacity targets support a steady flow of orders.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Nucleus_Software_Exports_performed_financially\"><\/span><strong>How has Nucleus Software Exports performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 532 crore in FY22 to Rs 940 crore in FY26, a compound annual growth rate of 15.3%. Net profit grew from Rs 40.9 crore in FY22 to Rs 117 crore in FY26, which works out to a compound annual growth rate of 30.0%. The company has a return on equity of 14.7%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,731 crore. The stock trades at a P\/E of 16.4, below the industry P\/E of 17.5. Looking ahead, the company is moving customers to cloud-based and subscription offerings, which build recurring revenue over time. Banks upgrading lending and transaction systems create steady demand for its platforms.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Emcure_Pharmaceuticals_performed_financially\"><\/span><strong>How has Emcure Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_solar_module_banking_software_and_drug_stocks\"><\/span><strong>What risks should investors check before buying solar module, banking software and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying solar module, banking software and drug stocks. Module prices. Solar equipment prices and policy support can change returns. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_solar_module_banking_software_and_drug_stocks_investment_advice\"><\/span><strong>Is this list of solar module, banking software and drug stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are solar module, banking software and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Solar module, banking software and drug stocks are listed companies that make solar photovoltaic modules, build software products for banks and lenders, and sell branded generics in India and other markets. Their earnings depend on solar installations, bank technology budgets and prescriptions. This list looks at three of them, Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which solar module, banking software and drug stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals. Based on the 4 November 2026 close, Saatvik Green Energy traded at Rs 368.5, Nucleus Software Exports at Rs 628.85 and Emcure Pharmaceuticals at Rs 2,160.4. Their return on equity ranges from 14.7% to 26.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 65.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do solar module, banking software and drug stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Solar module, banking software and drug stocks have a strong roadmap in India because large solar capacity plans, rising bank technology spending and steady demand for branded generics keep widening the market for these companies. The main drivers are as follows. Solar modules. Capacity additions need panels. Banking software. Lenders keep upgrading platforms. Branded generics. Doctors prescribe trusted brands. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Saatvik Green Energy performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 618 crore in FY22 to Rs 4,588 crore in FY26, a compound annual growth rate of 65.1%. Net profit grew from Rs 217 crore in FY25 to Rs 357 crore in FY26, a rise of 64.5%. The company has a return on equity of 26.2%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 4,934 crore. The stock trades at a P\/E of 20.1, below the industry P\/E of 43.9. Looking ahead, the company is adding module and cell capacity to meet rising demand for locally made solar equipment and is building a more integrated production chain. India's solar capacity targets support a steady flow of orders.\"}},{\"@type\":\"Question\",\"name\":\"How has Nucleus Software Exports performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 532 crore in FY22 to Rs 940 crore in FY26, a compound annual growth rate of 15.3%. Net profit grew from Rs 40.9 crore in FY22 to Rs 117 crore in FY26, which works out to a compound annual growth rate of 30.0%. The company has a return on equity of 14.7%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,731 crore. The stock trades at a P\/E of 16.4, below the industry P\/E of 17.5. Looking ahead, the company is moving customers to cloud-based and subscription offerings, which build recurring revenue over time. Banks upgrading lending and transaction systems create steady demand for its platforms.\"}},{\"@type\":\"Question\",\"name\":\"How has Emcure Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying solar module, banking software and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying solar module, banking software and drug stocks. Module prices. Solar equipment prices and policy support can change returns. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of solar module, banking software and drug stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Solar Module, Banking Software and Drug Stocks with a strong future roadmap: Saatvik Green Energy, Nucleus Software Exports and Emcure Pharmaceuticals. Compare price, valuation, return on equity and revenue growth as of 4 November 2026.<\/p>\n","protected":false},"author":28,"featured_media":340494,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[20648,3803,20649,13907,20650,20652,14862,20651,17204,11612],"class_list":["post-340495","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-banking-software-and-drug-stocks","tag-best-stocks","tag-clean-energy","tag-emcure-pharmaceuticals","tag-fintech-and-pharma-shares","tag-lending-platform-and-generic-stocks","tag-nucleus-software-exports","tag-photovoltaic-panel","tag-saatvik-green-energy","tag-solar-module"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340494"],"rank_math_title":["Solar Module, Banking Software and Drug Stocks"],"rank_math_description":["Compare 3 solar module, banking software and drug stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 4 Nov 2026."],"rank_math_focus_keyword":["solar module, banking software and drug stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-solar-photovoltaic-modules-maker-banking-software-products-company-and-branded.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340495"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340495\/revisions"}],"predecessor-version":[{"id":340496,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340495\/revisions\/340496"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340494"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}